Background/Objectives: There are no reliably effective, well-tolerated topical
| INTRODUCTION
Existing topical therapies for hyperhidrosis are limited. Response to topical aluminum chloride is often unsatisfactory, local skin tolerance to aluminum salts in the axillary region is poor, 1 and skin irritation often leads to poor adherence. Oral anticholinergics are an effective treatment for primary focal hyperhidrosis in children and adults, 2, 3 but anticholinergic side effects such as xerostomia and constipation often accompany oral administration. Topical administration of these agents may have the benefit of clinical efficacy with a lower total drug burden and a more favorable side-effect profile. 4 Oxybutynin is well suited for use as a transdermal agent. It is a small (393.95 kDa) tertiary amine molecule, and the unionized free base form of the drug predominates at physiologic pH. 5 It has a serum half-life of 62-84 hours when applied topically, 6 suggesting that treatment may have a longer duration of action than existing topical therapies such as aluminum chloride. Topical oxybutynin 3% gel is approved for the treatment of overactive bladder in adults. A pharmacologic effect of topical oxybutynin 3% gel on the bladder suggests that the DOI: 10.1111/pde.13404 compound may also have an effect at distant, untreated sites such as the hands and feet when applied to the axilla.
Additional studies are warranted to identify an effective, well-tolerated topical agent, which would obviate the need for oral therapy or invasive procedures. To our knowledge, no studies have evaluated topical oxybutynin gel as a treatment of hyperhidrosis. Thus, our primary objective was to determine whether daily application of topical oxybutynin 3% gel would reduce the symptoms of primary axillary hyperhidrosis in adolescents and young adults. We also evaluated the effect of daily topical oxybutynin 3% gel at distant, untreated sites; assessed the effect of daily topical oxybutynin 3% gel on healthrelated quality of life (HRQOL); and evaluated the local and systemic tolerability of topical oxybutynin 3% gel over 4 weeks of treatment.
| MATERIALS AND METHODS
The Colorado Multiple Institutional Review Board approved this study. Patients were 13-24 years old with moderate to severe axillary hyperhidrosis correlating with a score of 3 (sweating is barely tolerable and frequently interferes with daily activities) or 4 (sweating is intolerable and always interferes with daily activities) on the Hyperhidrosis Disease Severity Scale (HDSS). 7 Hyperhidrosis affected the bilateral axilla in all patients; patients with concurrent focal hyperhidrosis affecting the hands and feet were not excluded.
Patients were excluded if they had received botulinum toxin injections at any site in the preceding 12 weeks or treatment with other modalities (e.g., oral anticholinergics, topical aluminum chloride, iontophoresis) within 4 weeks of enrollment.
We collected clinical and demographic information on age, sex, age of hyperhidrosis onset, duration of disease, family history of hyperhidrosis, medical history, location of hyperhidrosis, and prior treatments. Before initiating therapy, severity of hyperhidrosis at each site was evaluated using the HDSS. Baseline HRQOL was evaluated using the Children's Dermatology Life Quality Index (CDLQI) in patients 12-17 years old and the Dermatology Life Quality Index (DLQI) in patients 18-25 years old. 8, 9 Scores range from 0 to 30, with a score of 0-1 indicating no effect on a patient's life and a score of 21-30 indicating an extremely large effect on a patient's life.
Patients were treated with 1 g of oxybutynin 3% gel to each axilla every morning and prospectively followed over 4 weeks. Response to treatment was assessed by calculating change in axillary HDSS from baseline to weeks 1 and 4. At each of these time periods, we also assessed change in CDLQI or DLQI; change in HDSS at distant, untreated sites (hands and feet); incidence of treatment-emergent systemic adverse effects according to daily patient diaries and investigator global review; and incidence and severity of application site skin irritation according to daily patient assessments and physician assessment.
Based on a prospective power analysis and sample size determination, we initially planned to enroll 20 patients in this study.
The primary outcome measure was change in hyperhidrosis severity from baseline to weeks 1 and 4 according to the HDSS.
We initially defined a treatment responder as any patient whose HDSS score improved from a baseline score of 3 or 4 to a score of 1 or 2 at week 1 or 4. We had planned to assess the primary outcome measure using a one-sample binomial test. The manufacturer discontinued the drug during the enrollment period, and we were unable to achieve our goal enrollment. Because of the small sample size, we elected to present the data descriptively.
3 | RESULTS
| Baseline data and noncompleters
Patient baseline characteristics and treatment course are presented in Table 1 . Ten patients were treated with oxybutynin 3% gel (one male, nine female). Patient ages at treatment initiation ranged from 13 to 24 years (mean AE standard deviation 18.5 AE 4.3 years). Four patients had isolated axillary hyperhidrosis (40%), and six (60%) had involvement of the axilla, hands, and feet. Nine patients (90%) had failed at least one other treatment modality. Prior treatments included aluminum chloride 20% solution only (n = 5), onabotulinumtoxinA injections only (n = 1), aluminum chloride 20% and onabotulinumtoxinA (n = 2), and aluminum chloride 20% and oral glycopyrrolate (n = 1). Seven patients completed the study, two were lost to follow-up (one before and one after the week 1 followup visit), and one was removed from the study at day 6 after experiencing a severe adverse event (SAE). reported no change at week 1 followed by a higher plantar HDSS at week 4 ( Figure 1C ).
| HDSS response

| CDLQI and DLQI
Six patients (85.7%) reported a reduction in CDLQI or DLQI score at weeks 1 and 4, and one (14.3%) reported an increase in score at weeks 1 and 4 ( Figure 1D ). In the seven patients who completed the study, mean CDLQI and DLQI scores improved from baseline (14) to weeks 1 (8.6) and 4 (7.1).
| Adverse events
Adverse effect data were available for nine patients (seven who completed the study, one who was lost to follow-up after the week 1 visit, one who was removed from the study at day 6 after experiencing a SAE). Three (33.3%) experienced a mild systemic adverse event; two (22.2%) reported xerostomia during the first week of treatment, and one reported constipation and blurry vision (11.1%). One (11.1%) experienced a SAE, pyelonephritis on day 6 of treatment resulting in hospital admission. Three (33.3%) reported mild (n = 1) or moderate (n = 2) application site skin irritation that resolved by the end of the study.
Physician assessment of local tissue tolerance at weeks 1 and 4 revealed no visible skin changes in any patient. All local and systemic adverse events had resolved by the 6-week follow-up telephone call. Although we observed a modest number of patients with application site irritation (3/9), patient-reported irritation was mild to moderate in severity, did not affect adherence to treatment protocol, and resolved spontaneously during treatment without intervention.
| DISCUSSION
Additionally, physician assessment of application site did not reveal physical evidence of application site reaction in any patients, including those who reported subjective irritation. When used for overactive bladder, oxybutynin gel is applied to the abdomen or proximal extremities. Drug application to a nonocclusive site might mitigate application site irritation.
Topical oxybutynin gel has a more favorable pharmacokinetic profile than the oral formulation. When taken orally, oxybutynin is subject to hepatic and gastrointestinal first-pass metabolism. 6 Its primary metabolite, N-desethyloxybutynin (N-DEO), is pharmacologically active but has a higher side effect-to-efficacy ratio than the This study provides limited prospective data supporting the use of topical oxybutynin 3% gel for the treatment of axillary hyperhidrosis. The manufacturer discontinued manufacture of the study drug during the enrollment period, and we were unable to achieve our goal enrollment. The decision to discontinue the product was business related and not due to product safety or efficacy. Oxybutynin 10% gel is also approved for the treatment of overactive bladder and remains commercially available. This study did not evaluate the drug's duration of action, an area of potential future research given its long serum half-life and the short duration of action of existing topical therapy with aluminum salts. All patients in this study applied the drug to axillary skin. The effect of drug application at other sites should be evaluated in a larger study. A large, randomized, double-blind, placebo-controlled trial that addresses these limitations is warranted.
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